<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03204019</url>
  </required_header>
  <id_info>
    <org_study_id>CH-GI-103</org_study_id>
    <nct_id>NCT03204019</nct_id>
  </id_info>
  <brief_title>A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor</brief_title>
  <official_title>A Phase II Randomized,Controlled,Open Label,Multicentre Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase II Randomized,Controlled,Open Label,Multicentre Study to evaluate the efficacy and
      safety of Tegafur combined with Temozolomide versus Tegafur combined with Temozolomide and
      Thalidomide in subjects with Advanced Pancreatic Neuroendocrine Tumor
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate(ORR)</measure>
    <time_frame>From randomization，each 6 weeks or 12 weeks(a year later) up to intolerance the toxicity or PD (up to 24 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate(DCR)</measure>
    <time_frame>From randomization，each 6 weeks or 12 weeks(a year later) up to intolerance the toxicity or PD (up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Response (TTR)</measure>
    <time_frame>From randomization，each 6 weeks or 12 weeks(a year later)up to PD or death(up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response(DOR)</measure>
    <time_frame>From randomization，each 6 weeks or 12 weeks(a year later) up to PD or death(up to 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival(PFS)</measure>
    <time_frame>From randomization，each 6 weeks or 12 weeks(a year later)(a year later) up to PD or death (up to 24 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pancreatic Neuroendocrine Tumor</condition>
  <arm_group>
    <arm_group_label>Tegafur and Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drugs should be continued until disease progression or intolerable toxicity or patients withdrawal of consent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tegafur and Temozolomide combined with Thalidomide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drugs should be continued until disease progression or intolerable toxicity or patients withdrawal of consent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegafur and Temozolomide</intervention_name>
    <description>Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qd(d10-d14)</description>
    <arm_group_label>Tegafur and Temozolomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegafur and Temozolomide combined with Thalidomide</intervention_name>
    <description>Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qe(d10-d14) Thalidomide 100mg po qd(d1-d7) /Thalidomide 200mg po qd(d8-d14)/Thalidomide 300mg po qd(d15-d21)</description>
    <arm_group_label>Tegafur and Temozolomide combined with Thalidomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients should participate in the study voluntarily and sign informed consent;

          2. Histopathological proven diagnosis of low and intermediate grade (G1, G2 or G3)
             advanced pancreatic neuroendocrine tumor( locally advanced, unresectable or distant
             Metastatic). For gastroenteropancreatic neuroendocrine tumor（GEP-NET）,the
             classification is based on nuclear mitotic number and the Ki-67 index,which are as
             follows:G1:Nuclear mitotic number &lt;2/10HPF,Ki-67 proliferative index ≤2%.G2: Nuclear
             mitotic number 2～20/10HPF,Ki-67 proliferative index 3%～20%.G3 Nuclear mitotic number
             ＞20/10HPF,Ki-67 proliferative index ＞20%;

          3. Patients with advanced PNENs who had not been treated or had no more than two kinds of
             Systemic Anti-tumor Therapy,which could be somatostatin analogs, interferon, PRRT
             (peptide receptor radionuclide therapy), mTOR inhibitors, or chemotherapy (without any
             use of azole amines, fluorouracil,or thalidomide chemotherapy drugs);

          4. Radiological documentation of tumor progression is required within 12 months prior to
             randomization;

          5. At least one measurable lesion (byRECIST1.1);

          6. ANC≥1.5×109/L,PLT≥100×109/L,HB≥90g/L,TBIL≤1.5ULN ;Without supportive care, ALT≤2.5ULN
             and ALP≤2.5ULN (without hepatic metastasis) ALT≤5ULN and ALP≤5ULN(with hepatic
             metastasis);serum creatin ≤1.5ULN and creatinine clearance rate ≥60ml/min；INR≤1.5ULN
             and APTT ≤1.5ULN ;

          7. ECOG PS:0-1;

          8. Life expectancy of more than 12 weeks;

          9. Men/Women of childbearing potential must agree to use a highly effective contraceptive
             method (such as double barrier contraceptive method，condom, oral or injectable
             contraceptives and intrauterine device) throughout treatment and for at least 90 days
             after study completion；All female patients will be considered fertile unless she has
             undergone natural menopause, artificial menopause or sterilization (such as
             hysterectomy, bilateral adnexal resection, or radioactive ovarian irradiation etc.)

        Exclusion Criteria:

          -  1、Diagnosed with high grade (G3) neuroendocrine carcinomas, adenocarcinoma, pancreatic
             islet cell carcinoma, goblet cell carcinoid, large cell neuroendocrine carcinoma, and
             small cell carcinoma; 2、Gastrointestinal tract, lung and thymus, and other unknown
             source of neuroendocrine tumors; 3、Functional NET which needs concomiant use of
             long-acting somatostatin analogues to control symptoms such as insulinoma, gastrinoma,
             glucagon tumor, somatostatin, ACTH tumor, VIP tumor, and carcinoid syndrome,
             Zollinger-Ellison syndrome or other disease-specific active symptoms.; 4、prior use of
             any VEGF/VEGFR targeted drugs and with disease progression during treatment; 5、Urine
             protein ≥ ++，or Urine protein detected by quantitative test of 24h urinary protein＞1.0
             g; 6、Serum potassium and calcium (ionic or albumin binding) or magnesium exceed normal
             range and have clinical significance; 7、 Blood pressure unable to be stably
             controlled(systolic pressure&gt;140 mmHg，diastolic pressure&gt;90mmHg); 8、gastrointestinal
             diseases or states judged by Investigators that could affect the absorption of the
             drug, including but not limited to active gastric and duodenal ulcers, ulcerative
             colitis or other gastrointestinal diseases or unresectable gastrointestinal tumor with
             active bleeding or other status that may cause gastrointestinal bleeding or
             perforation; 9、Patients have or had severe hemorrhage (bleeding volume &gt;30ml within 3
             months) , hemoptysis( fresh blood &gt;5ml within 4 weeks ) or thromboembolic events
             (including transient ischemic attack) within 12 months; 10、Cardiovascular disease with
             significant clinical significance, including but not limited to acute myocardial
             infarction, severe / unstable angina or coronary artery bypass surgery within 6 months
             prior to enrollment; congestive heart failure (New York Heart Association (NYHA)
             classification&gt; 2); ventricular arrhythmia requiring pharmacological treatment; left
             ventricular ejection fraction (LVEF) &lt;50%; 11、 Electrocardiogram (ECG) showed QT
             interval ≥480ms; 12、Patients suffered from other malignant tumors in the past 5
             years,except radical resection of skin basal cells or squamous cell carcinoma, or
             cervical carcinoma in situ; 13、patients who have received anti-tumor therapy within 4
             weeks prior to initiation of the study, including but not limited to chemotherapy,
             radiotherapy, bio-targeted therapy, immunotherapy, anti-tumor treatment of traditional
             Chinese medicine, hepatic artery embolization, hepatic metastatic cryoablation or
             radiofrequency ablation surgery; 14、patients who have received Palliative radiotherapy
             for bone metastaseswithin 2 weeks prior to initiation of the study ; 15、Any clinically
             significant active infection, including but not limited to HIV infection; 16、Patients
             with clinically significant liver disease history ,including but not limited to
             hepatitis B virus (HBV) infection (HBVDNA positive and copy number ≥1×104/ml);
             hepatitis C virus (HCV) infection,(HCVRNA positive and copy number≥1×103/ml), or
             cirrhosis; 17、Patients had surgery (except biopsy) within 28 days or has surgical
             incision not fully healed prior to initiation of the study; 18、Patients with brain
             metastasis or spinal cord compression which had not surgical and / or radiation
             therapy,or which had previous treatment but there is no clinical imaging evidence
             proving the condition is stable; 19、The toxic reaction of previous anticancer
             treatment has not restored to grade 0 or 1 (except hair loss); 20、Patients
             participated in other drug clinical trials within 4 weeks and received drug treatment
             ; 21、Pregnancy(Pregnancy test positive before drug use)or lactation; 22、any other
             disease, metabolic abnormality, abnormal physical examination, or laboratory
             abnormalities estimated by investigators that make the patients not suitable to
             receive the study drug or will affect the interpretation of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yihebali Chi, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yihebali Chi, doctor</last_name>
    <email>dryihebalichi@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hong Zhao, doctor</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yihebali Chi</last_name>
      <email>yihebalichi@yahoo.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2017</study_first_submitted>
  <study_first_submitted_qc>June 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2017</study_first_posted>
  <last_update_submitted>June 28, 2017</last_update_submitted>
  <last_update_submitted_qc>June 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>yihebali chi</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Tegafur</keyword>
  <keyword>Temozolomide</keyword>
  <keyword>Thalidomide</keyword>
  <keyword>Pancreatic Neuroendocrine Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Adenoma, Islet Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Tegafur</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

